Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Correlation Between Idiopathic Parkinson's Disease and Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03685357
Recruitment Status : Unknown
Verified September 2018 by Afnan Awad-Allah Elgnainy, Ain Shams University.
Recruitment status was:  Recruiting
First Posted : September 26, 2018
Last Update Posted : September 27, 2018
Sponsor:
Collaborator:
Al-Azhar University
Information provided by (Responsible Party):
Afnan Awad-Allah Elgnainy, Ain Shams University

Brief Summary:
Correlation between Idiopathic Parkinson's disease and diabetes mellitus in Egyptian Elderly Patients

Condition or disease
Observation

Detailed Description:
  1. Record RBDSQ ("Rapid eye movement Sleep" Behavior Disorder Screening Questionnaire) total score difference between Group 1 and Group 2 .
  2. Oral glucose tolerance test will be performed and compared between Group 3 and Group 4.
  3. Association between glucose level and motor complication of L-dopa among Idiopathic Parkinson's patients using Unified Parkinson's Disease Rating Scale (UDPRS).

Layout table for study information
Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Investigation of the Possible Correlation Between Idiopathic Parkinson's Disease and Diabetes Mellitus in Egyptian Elderly Patients
Actual Study Start Date : July 1, 2018
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine


Group/Cohort
Idiopathic Parkinson's

Oral glucose tolerance test

The Unified Parkinson's Disease Rating Scale (UDPRS).

Diabetics receive sulphonylurea group
Record RBDSQ ("Rapid eye movement Sleep" Behavior Disorder Screening Questionnaire) total score
Diabetics on sulphonylurea and metformin
Record RBDSQ ("Rapid eye movement Sleep" Behavior Disorder Screening Questionnaire) total score
Healthy

Record RBDSQ ("Rapid eye movement Sleep" Behavior Disorder Screening Questionnaire) total score

Oral glucose tolerance test




Primary Outcome Measures :
  1. UPDRS (Unified Parkinson's Disease Rating) Scale) [ Time Frame: Baseline ]
    Association between glucose level and motor complication of L-dopa among Idiopathic , , Parkinson's patients using Unified Parkinson's Disease Rating Scale (UDPRS)., high scores mean worsen condition

  2. Oral Glucose Tolerance Test [ Time Frame: 0, 0.5 hour , 1 hour, 1.5 hour , 2 hour ]
    Between Idiopathic Parkinson's patients and the Control group

  3. RBDSQ ("Rapid eye movement Sleep" Behavior Disorder Screening Questionnaire) [ Time Frame: Baseline ]
    among Diabetic Patients, total score 13 , high scores mean worsen condition


Biospecimen Retention:   Samples Without DNA
Blood Samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Egyptian Elderly
Criteria

Inclusion Criteria:

  1. Diabetic Patients
  2. Idiopathic Parkinsonism

Exclusion Criteria:

  1. Secondary Parkinsonism due to stroke, trauma and encephalitis.
  2. Drug induced Parkinsonism.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03685357


Contacts
Layout table for location contacts
Contact: Afnan Elgnainy 01061840761 Afnan.elgnainy@pharma.asu.edu.eg

Locations
Layout table for location information
Egypt
AinShams University Recruiting
Cairo, Egypt
Principal Investigator: Afnan Elgnainy         
Sponsors and Collaborators
Ain Shams University
Al-Azhar University
Investigators
Layout table for investigator information
Principal Investigator: Afnan Elgnainy AinShams University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Afnan Awad-Allah Elgnainy, Master student, teaching assistant of Clinical Pharmacy, Ain Shams University
ClinicalTrials.gov Identifier: NCT03685357    
Other Study ID Numbers: AinShamsUni Afnan
First Posted: September 26, 2018    Key Record Dates
Last Update Posted: September 27, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases